An earlier post stated that in its draft report, the Pharmaceutical Patents Review Panel had recommended against making the patent term extension regime under sections 70-79A of the Patents Act available for formulation patents and patents for methods of treatment.
The post should have stated that the Panel had recommended against making the extension regime available for patents for method of manufacture or methods of treatment. Formulation patents are already potentially eligible for an extension, and the Panel's draft report recommends that continue.
0 comments:
Post a Comment